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Differential expression of Toll-like receptor (TLR) by conventional dendritic cells (cDCs) 
and plasmacytoid DC (pDCs) has been suggested to influence the type of immune response 
induced by microbial pathogens. In this study we show that, in vivo, cDCs and pDCs are 
equally activated by TLR4, -7, and -9 ligands. Type I interferon (IFN) was important for pDC 
activation in vivo in response to all three TLR ligands, whereas cDCs required type I IFN 
signaling only for TLR9- and partially for TLR7-mediated activation. Although TLR ligands 
induced in situ migration of spleen cDC into the T cell area, spleen pDCs formed clusters in 
the marginal zone and in the outer T cell area 6 h after injection of TLR9 and TLR7 ligands, 
respectively. In vivo treatment with TLR9 ligands decreased pDC ability to migrate ex vivo in 
response to IFN-induced CXCR3 ligands and increased their response to CCR7 ligands. Unlike 
cDCs, the migration pattern of pDCs required type I IFN for induction of CXCR3 ligands and 
responsiveness to CCR7 ligands. These data demonstrate that mouse pDCs differ from cDCs 
in the in vivo response to TLR ligands, in terms of pattern and type I IFN requirement for 
activation and migration.
 
DCs are potent APCs that initiate T cell-depen-
dent immune responses (1). After exposure to
a variety of inflammatory stimuli, including
ligands for Toll-like receptors (TLRs; refer-
ence 2), DCs undergo phenotypic and func-
tional changes that characterize their transition
from immature to mature DCs exhibiting a
strong capability to initiate an immune re-
sponse. A complex modulation of chemokine
responsiveness and production is responsible
for mature/activated DC migration from the
peripheral tissues into the T cell areas of sec-
ondary lymphoid organs where DCs exert their
APC functions (3, 4).
DC subpopulations are characterized by
expression of different surface markers and
ability to produce cytokines that modulate
both innate resistance and adaptive immune
response (5). In humans, CD11c
 
-
 
 IL-3R
 
hi
 
 plas-
macytoid DCs (pDCs) differ from CD11c
 
 
 
conventional DCs (cDCs) in being uniquely
able to produce high levels of IFN-
 
 
 
 in response
to virus stimulation (6, 7) or to oligodeoxynu-
cleotides containing unmethylated CG motifs
(CpG-ODN; reference 8). In the mouse,
pDCs are CD11c
 
low
 
 B220
 
high
 
 Ly6C
 
high
 
 cells ex-
hibiting plasmacytoid morphology and able to
produce high level of IFN-
 
 
 
 on exposure to
several viruses or to CpG-ODN (9–11). Mouse
CD11c
 
high
 
 cDCs have been further subdivided
in subsets (5). The nature of the T cell re-
sponse on presentation of antigen by DCs is
dependent on the subpopulation of DCs in-
volved, the antigen dose, the cytokine environ-
ment, and the stage of maturation of presenting
DCs (12–14). DC subtypes also link acquired
and innate resistance responses (15), with cDCs
activating both B cells (16) and NK cells (17),
and pDCs producing large amounts of type I
IFN in response to viruses as well as playing an
essential role in activating NK cells to kill vi-
rus-infected cells (18).
The pattern of TLR expression in different
DC types and their interaction with specific
pathogen-derived ligands regulate cytokine
production and direct the type of immune re-
sponse (13, 19). The role of specific TLR in
mediating type I IFN production in response
to viral stimulation (in particular TLR3 and
-4 in cDCs and TLR7 and -9 in pDCs) has
recently been demonstrated (20–23). Type I
IFNs (IFN-
 
 
 
, -
 
 
 
, or -
 
 
 
) are cytokines exhibit-
ing antiviral activity as well as a variety of other
biological effects on macrophage function,
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NK cell activity, Th1 differentiation, CTL generation and
activity, and T cell survival and proliferation. They play a
central role in host resistance to viral or microbial infections
(24, 25) and are often considered important components
linking innate and adaptive immunity (24–26).
It has been suggested that type I IFN promotes and may
be necessary for human and mouse DC maturation, includ-
ing up-regulation of costimulatory molecules and ability to
stimulate T cells. A role for type I IFN in mouse DC activa-
tion after viral or TLR-mediated stimulation has been pro-
posed, largely on the basis of studies with DCs derived in
vitro from BM cells in the presence of GM-CSF (BM-DCs;
references 27, 28) that did not provide information on phys-
iological DC subsets and failed to mimic the in vivo situation
in which high amounts of type I IFN are produced. In par-
ticular, BM-DCs did not contain pDCs, the major type I
IFN producing cells in vivo in response to viruses and cer-
tain TLR-ligands. Although polyinosinic–polycytidylic acid
induces high IFN-
 
 
 
 production in cells other than pDCs,
including BM-DCs, LPS and CpG-ODN induce only low
levels of IFN-
 
 
 
 in BM-DCs (28). In the present study, we
demonstrate that mouse pDC and cDC subsets differ in type
I IFN requirements for in vivo activation and migration in-
duced by treatment with TLR ligands.
 
RESULTS
Type I IFN production in vivo after TLR ligand injection
 
We first investigated the ability of TLR4, -7, and -9 ligands
to induce type I IFN secretion in vivo. Both IFN-
 
 
 
 (as de-
tected by an ELISA measuring the mouse IFN-
 
 
 
1, -
 
 
 
4, -
 
 
 
5,
-
 
 
 
6, and -
 
 
 
9) and type I IFN (as detected by biological anti-
viral assay, in the presence of neutralizing anti-IFN-
 
 
 
) were
detectable in the serum of resiquimod- or CpG-ODN–
treated mice, with a peak at 2 h and 4 h, respectively (Fig. 1
A). No detectable level of IFN-
 
 
 
 and very low levels of type
I IFN (10 U/ml 
 
 
 
4.6) were detected in the serum of LPS-
treated mice only at 2 h after treatment (Fig. 1 A). Mouse
pDCs have previously been demonstrated to be the major
IFN-
 
 
 
 producing cells in vitro in response to CpG-ODN
and in vivo after virus infection (9). We investigated the na-
ture of the type I IFN–producing cells in vivo in response to
TLR7 and TLR9 ligands. After both resiquimod and CpG-
ODN treatment, only 120G8
 
 
 
CD11c
 
low
 
 pDCs expressed
intracellular IFN-
 
 
 
 (6.1% and 8.7% positive cells, respec-
tively; Fig. 1 B), whereas no staining could be detected in
CD11c
 
high
 
 cDCs (Fig. 1 B), B cells, T cells, macrophages, or
NK cells (unpublished data). To investigate the regulation by
type I IFN on its own production in vivo, WT and
IFNAR
 
 
 
/
 
 
 
 mice were treated with TLR4, -7, and -9
ligands. In IFNAR
 
 
 
/
 
 
 
 mice, both IFN-
 
 
 
 and type I IFN
production in vivo in response to CpG-ODN were almost
completely abolished 6 h after treatment (Fig. 1 C). In con-
trast, resiquimod-induced type I IFN production was similar
in WT and IFNAR
 
 
 
/
 
 
 
 mice 2 h after the treatment, al-
though IFN-
 
 
 
 secretion was decreased 
 
 
 
50% in the latter
(Fig. 1 C). A mixture of neutralizing rabbit anti-IFN-
 
 
 
 and
anti-IFN-
 
 
 
 polyclonal antibody (pAb) abolished more than
90% of the antiviral activity measured in the serum of re-
siquimod- and CpG-treated mice (unpublished data), indi-
cating that the antiviral activity was mostly caused by the
presence of IFN-
 
 
 
 and IFN-
 
 
 
. LPS in both WT and
IFNAR
 
 
 
/
 
 
 
 mice induced no detectable IFN-
 
 
 
 and very low
levels of type I IFN (Fig. 1 C), and LPS-induced type I IFN
antiviral activity was completely blocked by a neutralizing
rabbit anti-IFN-
 
 
 
 pAb (unpublished data). Thus, TLR7-
Figure 1. In vivo production of type I IFN in response to TLR ligands. 
(A) Sera from 129Sv WT mice were collected at different time point after 
LPS, resiquimod (R-848), or CpG-ODN treatment and titrated for IFN-  by 
ELISA and type I IFN by biological assay. The sera of mice injected with 
DOTAP alone were negative for IFN-  and type I IFN. Mean cytokine con-
centration (  SEM) of three mice per group is shown (two independent ex-
periments giving similar results). (B) Spleen cells from 129Sv WT mice were 
collected 3 h after PBS or CpG-ODN injection, or 1 h after resiquimod injec-
tion and stained, as described in Materials and methods. pDC were gated as 
120G8 CD11clow cells. CD11chigh DC were gated as 120G8 CD11chigh cells. 
Dot plots shown for each staining are representative of at least three de-
terminations in two separate experiments. (C) Sera from 129Sv WT mice or 
IFNAR /  mice were collected 2 h after PBS, LPS, or resiquimod treatment 
and 6 h after CpG-ODN treatment and titrated for IFN-  by ELISA and IFN 
type I by biological assay. Mean cytokine concentration (  SEM) of 6–16 
mice per group is shown (two to five independent experiments giving sim-
ilar results). *, P   0.01, compared with WT mice. 
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and TLR9-induced type I IFN and IFN-
 
 
 
 secretion are dif-
ferentially regulated by type I IFN in vivo.
 
Role of type I IFN in TLR-mediated activation of DC subsets
 
We next investigated the role of type I IFN signaling in
TLR-mediated in vivo activation of DC subsets. Activation
of DC subsets was studied 6 h after injection of TLR ligands
in both WT and IFNAR
 
 
 
/
 
 
 
 mice. pDCs freshly isolated
from untreated WT and IFNAR
 
 
 
/
 
 
 
 mice had similar levels
of CD40 and CD86 expression (Fig. 2 A). 120G8
 
 
 
 pDCs
from WT mice up-regulated both CD40 and CD86 expres-
sion after LPS, resiquimod, or CpG-ODN treatment in
vivo. This up-regulation was absent or much reduced in
pDCs from IFNAR
 
 
 
/
 
 
 
 mice (Fig. 2 A).
In response to LPS, resiquimod, or CpG-ODN treat-
ment in vivo, both CD8
 
 
 
 
 
 CD11c
 
high
 
 and CD8
 
 
 
 
 
CD11c
 
high
 
 subsets of cDCs from WT mice modestly up-reg-
ulated CD40 (unpublished data) and strongly up-regulated
CD86 (Fig. 2 A). However, both cDC subsets from
IFNAR
 
 
 
/
 
 
 
 mice failed to up-regulate CD86 after CpG-
ODN stimulation in vivo, whereas LPS induced a compara-
ble increase of CD86 expression level in both WT and
IFNAR
 
 
 
/
 
 
 
 mice (Fig. 2 A). In response to resiquimod in
vivo, the increase in CD86 expression was negligible in the
CD8
 
 
 
 
 
 cDCs from IFNAR
 
 
 
/
 
 
 
 mice and was significantly
lower in CD8
 
 
 
 
 
 cDCs from IFNAR
 
 
 
/
 
 
 
 mice than in
CD8
 
 
 
 
 
 cDCs and CD8
 
 
 
 
 
 cDCs from WT mice (Fig. 2 A).
To elucidate the role of type I IFN secretion in TLR-
mediated activation of purified pDCs, spleen 120G8
 
 
 
CD11c
 
low
 
 pDCs were isolated by fluorescence-activated cell
sorting from WT 129 mice and IFNAR
 
 
 
/
 
 
 
 mice. The puri-
fied pDCs were then cultured in vitro for 20 h in the pres-
ence or absence of LPS, resiquimod, or CpG-ODN. Al-
though isolated pDCs from WT mice slightly up-regulated
CD40 and CD86 after 18 h culture in the absence of TLR
ligands (unpublished data and Fig. 2, A and B), the cultured
pDCs from IFNAR
 
 
 
/
 
 
 
 mice exhibited a lower level of
CD40 and CD86 expression than those from WT mice (Fig.
2 B). pDCs from WT mice cultured in the presence of
CpG-ODN or resiquimod, and, to a lower extent, LPS,
strongly up-regulated both CD40 and CD86 (Fig. 2 B). In
pDCs from IFNAR
 
 
 
/
 
 
 
 mice, the up-regulation of CD40
and CD86 in response to CpG-ODN was abolished. In con-
trast, pDCs from IFNAR
 
 
 
/
 
 
 
 mice up-regulated both CD40
and CD86 in response to resiquimod and LPS, although the
level of expression was much reduced compared with that
observed in pDCs from WT mice.
 
Migration of spleen DC subsets
 
In vivo DC activation by microbial products, such as LPS or
extracts of 
 
Toxoplasma gondii
 
 and 
 
Leishmania donovani
 
, has
been shown to induce migration of CD11c
 
high
 
 cDCs from
the marginal zone and outer periarteriolar lymphatic sheaths
(PALs) into the T cell area (29, 30). Using the 120G8 mAb
that detects an antigen highly expressed on both resting and
activated pDCs (31), we have investigated the migration of
pDCs within spleen in mice treated with TLR ligands. We
have compared it with that of cDCs identified as CD11c
 
high
 
.
Because of the low expression of CD11c on pDCs, immu-
nohistochemical staining with anti-CD11c and 120G8 al-
lowed us to distinguish between pDCs and cDCs (31). In
untreated mice, 120G8
 
 
 
 pDCs were scattered mainly in the
T cell area and in the red pulp, although, rarely, pDCs could
be detected in the marginal zone (Fig. 3 A). In contrast,
CD11c
 
high
 
 cDCs were mostly located in the outer PALs and
in the marginal zone, with few cDCs detected in the red
pulp (Fig. 3 A). At 6 h after treatment with LPS, spleen
Figure 2. Mouse DC subset activation in response to TLR ligands. 
(A) Spleen cells from 129Sv WT mice or IFNAR /  mice, treated with PBS, 
LPS, resiquimod (R-848), or CpG-ODN, were collected 6 h after treatment 
and stained as described in Materials and methods. CD40 (left panels) and 
CD86 (right panels) expression on 120G8 CD11clo pDC (upper panels), 
only CD86 on CD8  cDC (lower right panel), and CD8  cDC (lower left 
panel) were analyzed. Mean fluorescence intensity (MFI)   SEM of six 
mice per group (two independent experiments giving similar results) is 
shown. (B) Sorted 120G8 CD11clow pDC were isolated from 129Sv WT 
mice or IFNAR /  mice and stimulated with medium, LPS, resiquimod, or 
CpG-ODN as described in Materials and methods. MFI   SEM of CD40 (left 
panels) and CD86 (right panels) expression is shown for three independent 
experiments. *, P   0.05; **, P   0.01, compared with WT mice.PDC IN VIVO ACTIVATION AND MIGRATION | Asselin-Paturel et al. 1160
pDCs remained scattered in the T cell area and in the red
pulp (Fig. 3 B). At 6 h after treatment with CpG-ODN and
resiquimod, although some isolated pDCs could still be de-
tected in the red pulp, most spleen pDCs formed clusters in
the marginal zone and in the T cell area (Fig. 3, C and D).
Although CpG-ODN treatment induced pDC clusters
mostly located in the marginal zone (Fig. 3 D), after resiqui-
mod treatment those clusters were located in the T cell area
rather than in the marginal zone, and some isolated pDCs
could be detected in the T cell area (Fig. 3 C). Unlike pDCs,
cDCs migrated in the inner T cell area in response to all the
three TLR ligands tested (Fig. 3, A–D). Enumeration of to-
tal number of spleen pDCs revealed that pDC number de-
creased by approximately one half to one third at 6 h after all
TLR treatment. At 24 h after treatment with CpG-ODN or
resiquimod, only a minimal recovery of pDC number was
observed (Fig. S1, available at http://www.jem.org/cgi/
content/full/jem.20041930/DC1).
Role of type I IFN in TLR-mediated spleen pDC migration
We next addressed the question whether type I IFN would
play a role in spleen pDC migration in response to TLR7
and -9 ligands. No change in spleen pDC localization was
observed 6 h after injection of recombinant mouse IFN- 
(unpublished data). As previously reported (31), the intensity
of 120G8 staining was lower in IFNAR /  mice than in
WT mice. In untreated IFNAR /  mice, scattered spleen
120G8  pDCs were detected both in the T cell area and
in the red pulp, as in normal WT mice (Fig. 3 E). Unlike in
WT mice, spleen 120G8  pDC did not form clusters in
CpG-ODN- or resiquimod-treated IFNAR /  mice. Scat-
tered pDCs were found both in the T cell area and in the red
pulp. Strikingly, although some pDC were found in the
marginal zone of CpG-ODN–treated IFNAR /  mice, they
were mostly located in the T cell area, unlike in WT mice
(Fig. 3, F and G). In contrast, CD11chigh cDCs migrated to
the T cell area in IFNAR /  mice treated with CpG-ODN
or resiquimod, similarly to WT mice (Fig. 3, F and G).
Kinetics of pDC in situ migration in response to CpG-ODN 
and resiquimod
To characterize spleen pDC migration in response to TLR7-
and TLR9-mediated activation further, double immuno-
histofluorescent staining with 120G8 mAb and anti-CD3,
anti-CD11c, or anti-CD19 mAb was performed on spleen
sections from PBS-, CpG-ODN–, and resiquimod-treated
mice, at 6 h and 24 h after treatment (Fig. 4). In untreated
mice, as described in Fig. 3 A, 120G8  pDCs were scattered
in the T cell area and colocalized with cDCs only in the
outer PALs. At 2 h and 4 h after resiquimod treatment, no
pDC clusters were detected, and 120G8  pDCs were dis-
tributed both in the red pulp and the T cell area, with a pat-
tern of localization similar to that in spleens from untreated
mice (unpublished data). At 6 h after resiquimod treatment,
120G8  pDCs formed clusters in the T cell area (Fig. 4 B),
and cDCs were distributed throughout the entire T cell area
(Fig. 4 B). However, although an analysis of many sections
showed that at 6 h the clusters of pDCs were predominant in
the outer T cell area, at 24 h most 120G8  pDCs were
closer to the central artery (Fig. 4 C). At 6 h after CpG-
ODN treatment, clusters of 120G8  pDCs were localized in
the marginal zone (as identified by staining with ER-TR9
mAb, unpublished data) but not in the T cell area identified
by anti-CD3 staining (Fig. 4 D). CD11chgh cDCs did not
colocalize with 120G8  pDCs at 6 h after CpG-ODN treat-
ment (Fig. 4 D). In contrast, at 24 h after treatment, the clus-
ters of 120G8  pDCs were localized inside the T cell area
and colocalized with CD11chigh cDCs (Fig. 4 E).
Figure 3. Spleen dendritic cells localization after TLR treatment. 
(A–D) Spleens from 129Sv WT mice were collected 6 h after treatment 
with (A) PBS, (B) LPS, (C) resiquimod (R-848), or (D) CpG-ODN. (E–G) 
Spleens from IFNAR /  mice were collected 6 h after treatment with (E) 
PBS, (F) resiquimod, or (G) CpG-ODN. Spleen serial sections were obtained 
and stained with 120G8 (pDC, left panels), anti-CD11c (cDC, middle panels) 
or anti-CD3  (T cells, right panels) Abs as described in Materials and meth-
ods. One representative staining out of three mice per group is shown 
(two independent stainings). a, arteriol.JEM VOL. 201, April 4, 2005 1161
ARTICLE
Possible involvement of CXCR3 and CCR7 in pDC 
migration pattern
Migration of pDCs into inflamed lymph node has been sug-
gested to be initially mediated by CXCR4 and CXCR3
ligands (32). Chemokines such as CCR7 ligands also play a
major role in migration of activated DCs from peripheral tis-
sue into lymphoid organs (33). We investigated the ability of
in vivo CpG-ODN–activated spleen pDCs to migrate in
vitro in response to CXCR3 , CXCR4, or CCR7 ligands.
Mice were injected intravenously with CpG-ODN, and
spleens were collected at 0, 2, 6, and 24 h after treatment.
pDCs from untreated mice migrated in response to CXCR4
ligands (CXCL12), CXCR3 ligands (CXCL9), and CCR7
ligands (CCL19, CCL21), but not in response to CCR6 ligands
(CCL20) (Fig. 5 A). The migration index of pDCs in
response to CXCL12 remained constant at the different time
points after in vivo activation with CpG-ODN. The pDC
migration in vitro in response to CXCL9 was decreased as
early as 2 h after CpG-ODN injection, whereas pDC ability
to migrate in vitro in response to both CCR7 ligands CCL19
and CCL21 was up-regulated 6 h after CpG-ODN treatment
in vivo. The role of type I IFN in migratory response of acti-
vated pDCs to CXCL9 and CCL21 was further investigated.
The migration index of pDCs in response to CXCL9 was
slightly higher in untreated IFNAR /  mice than in WT
mice, whereas in vitro CCL21 induced a comparable migra-
tion of untreated pDCs in WT and IFNAR /  mice. At 6 h
after CpG-ODN treatment, the capacity of IFNAR / 
pDCs to migrate in response to CXCL9 was not significantly
reduced compared with PBS treatment. In contrast, the abil-
ity of IFNAR /  pDCs to migrate in vitro in response to
CCL21 was up-regulated at 6 h after CpG-ODN treatment,
although to a lower extent than in WT mice (Fig. 5 B).
The expression and localization of both CXCR3 and
CCR7 ligands were investigated in WT and IFNAR / 
mice. Although no CCL21 could be detected in WT and
IFNAR /  mice serum at 2 and 6 h after CpG-ODN treat-
ment (unpublished data), cells positive for CCL21 staining
were detected in the spleen T cell area of both untreated and
CpG-ODN–treated WT and IFNAR /  mice (Fig. 5 C).
Similar observations were obtained in resiquimod-treated
WT mice (Fig. 5 C). Both CXCL9 and CXCL10 were de-
tected in the serum of CpG-ODN–treated mice 6 h after in-
jection (5.45 ng/ml  1.9 and 2.04 ng/ml  0.9, respec-
tively). In resiquimod-treated mice, both chemokines were
already secreted at 2 h after injection and were minimally
decreased at 6 h after injection (7.4 ng/ml  0.3 and 2.1 ng/
ml  0.38, respectively). Secretion of both chemokines was
much reduced in the serum of CpG-treated IFNAR / 
mice compared with WT mice (CXCL9: 0.27 ng/ml  0.5;
CXCL10: 0 ng/ml in IFNAR /  mice; detection limit  
0.1 ng/ml). No staining using anti-CXCL10 goat pAb could
be observed in spleens from treated and untreated WT and
IFNAR /  mice (unpublished data). Using anti-CXCL9
goat pAb, no specific staining could be detected in spleens
from untreated WT mice. In contrast, at 6 h after CpG-
ODN and resiquimod injection, cells brightly positive for
CXCL9 intracellular expression were observed in the red
pulp (Fig. 5 C). Some additional CXCL9  cells were de-
tected in the spleen T cell area of resiquimod-treated WT
mice (Fig. 5 C). Spleens of CpG-treated IFNAR /  mice
displayed a pattern of CXCL9 staining similar to that of WT
mice (Fig. 5 C), although the staining intensity was lower.
Mouse pDC localize in the marginal zone after 
virus stimulation
To investigate whether spleen pDCs display a pattern of mi-
gration after virus infection similar to that seen with TLR
treatment, mice were injected i.p. with infectious murine cy-
tomegalovirus (MCMV). Viral infection and TLR ligand
treatment induced different kinetics of cytokine and chemo-
kine production. It has been reported previously that the peak
of type I IFN secretion, detected at 36 h after in vivo MCMV
Figure 4. Kinetics of spleen pDC in situ migration after resiquimod 
(R-848) or CpG-ODN treatment. Spleen from 129Sv mice were collected 
at 6 h or 24 h after (A) PBS, (B, C) R-848, or (D, E) CpG-ODN treatment, as 
described in Materials and methods. Spleen serial sections were obtained 
and costained with 120G8 in green and in red: anti-CD3  (left panels), anti-
CD11c (middle panels), or anti-CD19 (right panels) Abs, as described in Ma-
terials and methods. Overlaid pictures of the two fluorescences on identical 
sections are shown, for one representative mouse of three per group. a,
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infection, is dependent on the presence of pDCs (9). Thus, we
investigated the pattern of pDC migration at this crucial time
point. Thirty-six hours after MCMV infection, clusters of
120G8  pDCs were observed in the marginal zone of the
spleen, whereas CD11chigh cDCs redistributed to the T cell
area (Fig. 6, A and B). To confirm that 120G8  pDC were
type I IFN–producing cells after MCMV infection, we per-
formed double staining with 120G8 mAb and rat anti–mouse
IFN-  mAb on spleen sections from 1.5-d MCMV-infected
mice. Some nonspecific staining could be detected with anti-
IFN-  antibody, on endothelial cells from both uninfected
and infected mice (unpublished data). However, positive and
strong immunostaining for IFN-  was detected in the mar-
ginal zone of MCMV infected mice only. Cells positive for
IFN-  were also positive for 120G8 staining. In contrast,
some 120G8  pDC clusters did not stain for IFN-  (Fig. 6 C).
DISCUSSION
pDCs and cDCs express different TLR (8, 13, 34). In the
mouse, it has been reported that although TLR9 is expressed
on pDCs and cDCs, TLR7 is present on pDCs and CD8  
CD11chigh cDCs but is absent on CD8  CD11chigh cDCs
(19). Although TLR4 is highly expressed on BM-derived my-
eloid DCs, it is expressed only at a low level on spleen cDCs
and pDCs (13). Data on TLR expression and TLR-mediated
activation of in vitro derived DCs and ex vivo isolated DC
subsets have often been used to speculate on the ability of nat-
ural TLR ligands to activate DC subsets differentially during
infections. However, our data indicate that DC subsets are
equally activated with in vivo treatment with TLR ligands
such as LPS, CpG-ODN, or resiquimod. Particularly striking
is the in vivo activation by resiquimod of CD8  CD11chigh
DCs that do not express TLR7 and that are not activated in
vitro by TLR7 ligands (19). Indeed, to understand in vivo DC
activation during infections or on treatment with TLR
ligands, cellular and humoral interactions should be considered
not only among the DC subsets, but also with other immune
and nonimmune cells responding to TLR ligands.
It has been shown that DCs derived in vitro in the pres-
ence of GM-CSF or ex vivo isolated total spleen DCs spon-
Figure 5. Role of CCL21 and CXCL9 chemokines in migration of 
CpG-activated mouse pDC in the spleen. (A) Spleens from 129Sv mice 
were isolated 0 h, 2 h, 6 h, and 24 h after CpG-ODN in vivo treatment. 
Response of activated spleen pDC to various chemokines was studied in 
Transwell (Corning, Inc.) migration assay. Results are expressed as a migra-
tion index (number of migrating cells in chemokine/number of migrating 
cells in medium). One representative experiment three is shown. (B) Spleens 
from 129Sv WT and IFNAR /  mice were isolated 6 h after PBS or CpG-ODN 
in vivo treatment. Response of activated spleen pDC to CXCL9 and CCL21 
was studied in Transwell migration assay. Mean migration index from at 
least three independent experiments is shown. (C) Spleens from 129Sv WT 
and IFNAR /  mice were collected 6 h after treatment with PBS, CpG-ODN, 
or resiquimod. Spleen sections were obtained and stained with anti-CXCL9 
(left panels) or -CCL21 (right panels) Abs as described in Materials and 
methods. One representative staining out of three mice per group is shown. 
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taneously secrete type I IFN that acts in an autocrine manner
to promote their functional and phenotypic maturation (35,
36). Consistent with those data, we observed that pDCs (Fig.
2, A and C) and, to a lesser extent, cDCs from IFNAR / 
mice (unpublished data) in neutral culture conditions under-
went a lower maturation than DCs from control WT mice,
although no type I IFN secretion was detected under those
conditions. DCs freshly isolated from IFNAR /  and WT
mice expressed comparable low levels of maturation/activa-
tion markers (Fig. 2). No significant differences in DC fre-
quency could be detected in various organs from WT and
IFNAR /  mice (unpublished data), suggesting that, in non-
inflammatory conditions, the in vivo development of both
pDCs and cDCs does not require endogenous type I IFN.
The in vivo activation of pDCs in response to TLR
ligands, as analyzed by up-regulation of expression of CD40
and CD86, was profoundly depressed in IFNAR /  mice. In
contrast, type I IFN played a major role in the activation of
both subsets of cDCs as analyzed by up-regulation of CD86,
but only after treatment with CpG-ODN and, in part, with
resiquimod. Indeed, in vivo, LPS-mediated CD86 expression
on cDCs was not dependent on type I IFN signaling. Up-reg-
ulation of CD40 in vivo in cDCs was modest, and a possible
role for type I IFN could not be reliably evaluated.
Type I IFN played a major role in CpG-ODN–mediated
but not in LPS- or resiquimod-mediated in vitro activation
of sorted pDCs. This finding is consistent with the observa-
tion that sorted pDCs produced high amounts of IFN-  and
type I IFN in vitro in response to CpG-ODN, but not in re-
sponse to LPS, and produced very low levels in response to
resiquimod (unpublished data), although in vivo pDCs pro-
duced high levels of IFN-  after resiquimod treatment. Our
unpublished observations on sorted cDC subsets indicated
that in response to resiquimod and CpG-ODN in vitro,
these cells did not produce type I IFN, and that their activa-
tion was type I IFN independent. However, as previously
reported for LPS-induced CD40 expression in BM-DCs
(27, 28), LPS-mediated CD11b  cDC activation in vitro
was reduced in IFNAR /  mice, although LPS-activated
sorted cDCs secreted no detectable level of type I IFN (un-
published data). Taken together, our results suggest an in-
trinsic dependence of pDCs on type I IFN for optimal acti-
vation in vivo in response to several TLR ligands, and only a
partial and indirect dependence of cDCs, mostly observed
under in vivo conditions, that results in high systemic type I
IFN secretion by pDCs.
The migration pattern of activated cDCs in spleen has
been extensively studied, but little or no information is avail-
able for pDCs. In the spleen of untreated mice, as we previ-
ously described, pDCs are dispersed through the T cell area
but are also scattered in the marginal zone and red pulp (31).
cDCs, unlike pDCs, are mostly localized in the marginal
zone bridging channel, and only few interdigitating DCs are
present in the T cell zone (37). In the spleen of CpG-ODN–
or resiquimod-treated mice, CD11chigh cDCs, similar to pre-
vious descriptions of response to LPS or T. gondii extracts
(30), migrated from the bridging channel into the T cell
area, whereas pDCs formed clusters and displayed very spe-
cific changes in anatomic localization. After resiquimod
treatment, the clusters of pDCs were present in the T cell
zone, primarily in the outer PALs at 6 h after treatment, but
by 24 h pDCs were also present in the inner PALs. At 24 h
after treatment with CpG-ODN, pDC clusters were also
observed in the T cell zone, but at 6 h, the pDC clusters
were mostly found in the marginal zone, separated from the
majority of T cells and cDCs. Thus, unlike cDCs, pDCs are
not in contact with T cells soon after CpG-ODN treatment,
but later they partially colocalized with T cells and cDCs.
Whether the late localization of pDCs in the T cell area re-
flects a migration of the pDCs that clustered in the marginal
zone at earlier times or the entry of new pDCs in the in-
flamed spleen via the central artery remains to be investi-
gated. Indeed, although the total number of spleen pDCs
decreased after TLR treatment, this reduction does not ex-
clude the possibility that, although activated pDCs undergo
massive cell death, some newly activated pDCs might enter
the T cell area.
In mice exposed to either infectious MCMV (Fig. 6) or
inactivated HSV (unpublished data), pDCs migrated and ag-
gregated in the marginal zone, much as observed at 6 h after
CpG-ODN treatment. At 36 h after infection, IFN- –pro-
ducing cells colocalized in the marginal zone with clusters of
pDCs, although some clusters of activated pDCs did not
produce IFN- . This lack of IFN-  could result from differ-
ent kinetics between activation, migration, clustering, and
IFN production. At later time points, a dramatic decrease in
pDC frequency, as well as the lytic properties of MCMV in-
fection in vivo, prevented us from following the fate of pDC
Figure 6.  Dendritic cells localization in mouse spleens after MCMV 
infection. Spleens from 129Sv WT mice were collected 1.5 d after viral 
infection with MCMV. Spleen sections were stained with (A) 120G8 (pDC) 
or (B) anti-CD11c (cDC) Abs as described in Materials and methods. (C) 
Spleen sections were costained with 120G8 in green and anti-IFN  mAb 
in red, as described in Materials and methods. Overlaid pictures of the two 
fluorescences on identical sections are shown, for one representative 
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clusters (unpublished data). These data are consistent with an
early report demonstrating that after HSV-1 stimulation,
IFN-producing cells, now identified as pDCs, could be de-
tected in the spleen marginal zone (38).
Human and mouse resting pDCs previously have been
shown to respond spontaneously to CXCL12, a CXCR4
ligand found on high endothelial venules in human tonsils or
lymph nodes (32, 39). Human pDCs do not migrate in re-
sponse to CXCR3 ligands in vitro, but exposure or pretreat-
ment to inflammatory CXCR3 ligands drastically enhances
their ability to migrate in response to the constitutive che-
mokine CXCL12 (32, 40). This feature has been shown to
be important both for pDC migration to inflamed tissues
and for pDC transmigration through high endothelial
venules into inflamed lymph nodes (41). In addition, up-
regulation of CCR7 and responsiveness to the CCR7
ligands CCL21 and CCL19 has been shown to be involved
in migration of cDCs from peripheral tissue to lymphoid or-
gans and from the marginal zone bridging channel into the T
cell area where these chemokines are produced and are also
responsible for attraction of naive T cells. In accordance with
their respective TLR expression, human blood CD11c 
myeloid DCs up-regulate CCR7 and down-regulate CCR5
in response to LPS but not in response to CpG-ODN,
whereas human blood pDCs up-regulate CCR7 and down-
regulate CXCR3 in response to CpG-ODN but not in re-
sponse to LPS (34). We now show that mouse spleen pDCs,
6 h after in vivo treatment with CpG-ODN, acquire the
ability to migrate in response to the CCR7 ligand CCL21.
We also demonstrate that the capacity of spleen pDCs to mi-
grate in response to the CXCR3 ligand CXCL9 decreases
starting at 2 h after in vivo treatment with CpG-ODN, as
previously reported in vitro for mouse BM-derived pDCs,
consistent with the down-regulation of CXCR3 expression
upon ligation with its specific ligand (32). CXCL9 is pro-
duced after CpG-ODN treatment in the red pulp and mar-
ginal zone, but not in the PALs. Taken together, these data
suggest that the initial migration and clustering of mouse
pDCs after CpG-ODN treatment in the marginal zone re-
sults from their ability to migrate toward a gradient of con-
stitutive CXCL12 and of CXCR3 ligands such as CXCL9
induced by IFN and other proinflammatory cytokines in
the red pulp. At later time points, when the response to
CXCR3 ligands decreases and is followed by an increase in
the response to CCR7 ligands, pDCs, like cDCs, may mi-
grate or accumulate into the T cell area where CCL21 is
constitutively produced. It is not known why early pDC
clustering in the marginal zone is not observed in response to
treatment with the TLR7 ligand, resiquimod. resiquimod
and CpG-ODN treatment induced similar levels of both
CXCR3 ligands, CXCL9 and CXCL10, in the serum of
treated mice, as well as highly positive CXCL9 cells located
in the spleen red pulp. However, the very different kinetics
of cytokine and chemokine production, as well as pDC acti-
vation in response to TLR7 and -9 ligands on one hand, and
the presence of CXCL9  cells in the spleen T cell area of re-
siquimod-treated mice on the other hand, may provide some
explanations for this difference. Thus, the overall migration
pattern of pDCs after TLR treatment seems to involve a
complex interplay between chemokine receptor expression
by pDCs and chemokine secretion (kinetic and pattern) by
both pDCs and non-pDCs.
pDCs and cDCs differentially require type I IFN for in
situ migration in response to TLR ligands. Indeed, neither
aggregation nor migration of pDCs outside the T cell area
was observed in IFNAR /  mice in response to CpG-
ODN. After resiquimod treatment, no aggregation of pDCs
in the T cell area could be observed in IFNAR /  mice.
However, because resiquimod-activated pDCs are mostly
located in the T cell area in both WT and IFNAR /  mice,
it is difficult to reach conclusions about the role of type I
IFN in TLR7-induced pDC migration. In contrast, cDCs
still displayed the characteristic migration in the T cell area
in IFNAR /  mice.
Previous studies have shown that type I IFN signaling is
required for maturation but not for up-regulation of CCR7
on BM-DC or migration of cDCs in response to Newcastle
Disease Virus and polyinosinic–polycytidylic acid in vivo
(27). Similarly, pDCs from CpG-ODN–treated IFNAR / 
mice still up-regulated their responsiveness to CCR7 ligand
CCL21, although to a lesser extent than in WT mice. Al-
though some CXCL9-producing cells could still be detected
in the spleen of CpG-treated IFNAR /  mice, in vivo se-
cretion of both CXCL10 and CXCL9 was much decreased
in the serum of CpG-treated IFNAR /  mice, compared
with WT mice. Moreover, because CXCR3 expression is
down-regulated on ligation with CXCR3 ligands (32), a
lower secretion of type I IFN–regulated CXCR3 ligands in
IFNAR /  mice may explain both the higher level of
CXCR3 expression in resting pDCs and the absence of
CXCR3 down-regulation after CpG-treatment. Thus,
while cDCs need to up-regulate CCR7 to migrate in re-
sponse to CCR7 ligands, the expression of which is consti-
tutive and type I IFN independent. In contrast, the early
pDC clustering and migration may depend on the intrinsic
ability of these cells to migrate in response to a combined
gradient of constitutively expressed CXCL12 and type I
IFN–induced CXCL9 and CXCL10 in inflammatory condi-
tions. The need for induction of IFN-dependent inflamma-
tory chemokines in the early hours of response, as well as the
fact that, unlike cDCs, in pDCs the maturation and func-
tional activation, including up-regulation of CCR7, is re-
duced in the absence of type I IFN, could in part explain the
different type I IFN requirements for in situ migration of
cDCs and pDCs.
The localization of the pDCs in different spleen com-
partments during the inflammatory response may be impor-
tant for their ability to affect the response by secreting cyto-
kine (e.g., type I IFN) or to interact with T cells directly.
Interestingly, in response to viruses, TLR ligands, orJEM VOL. 201, April 4, 2005 1165
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CD40L, pDCs produce CXCL9 and CXCL10 and, through
their production of type I IFN, can recruit immature cDCs
to produce high amounts of inflammatory chemokines,
which may exert a chemotactic effect on CD8  effector T
cells and NK cells (32, 42, 43). One striking characteristic of
in vivo pDC activation is their tight clustering. It remains to
be determined whether the autocrine pDC production of
inflammatory chemokines during activation plays a role in
inducing their aggregation, possibly in addition of cross-
activation via type I IFN and activation of adhesion
molecules.
MATERIALS AND METHODS
Mice, culture medium, and antibodies. Specific pathogen-free female
129/SvPas mice, 6–10 wk of age, were purchased from Charles River.
IFNAR /  mice (A129 strain, mice deficient for the  1 chain of type I IFN
receptor) were purchased from B&K Universal Ltd. and bred by Charles
River. All mice experiments were performed following protocols approved
by the institutional animal committee and in accordance with European
Economic Community Council Directive 86/609 as well as institutional
animal care and use guidelines.
Primary cells were cultured in complete medium: RPMI 1640 (Life
Technologies) supplemented with 10% (vol/vol) heat-inactivated FCS (Life
Technologies), 2 mM L-glutamine (Life Technologies), 80  g/ml gentamy-
cine (Schering-Plough Corporation), 10 mM Hepes (Life Technologies),
and 50  M  2-mercaptoethanol (Sigma-Aldrich), at 37 C in 5% CO2. All
antibodies were from BD Biosciences unless otherwise specified.
In vivo treatment. For in vivo treatment with TLR ligands, mice were
anesthetized and injected i.v. in the retro-orbital vein with 200  l of PBS
(Life Technologies), LPS (5  g in 200  l of PBS, Sigma-Aldrich), resiqui-
mod (R-848, 5  g in 200  l of PBS; Invitrogen), or CpG-ODN prepara-
tion. This preparation consisted of 5  g of CpG-ODN (TCA TTG GAA
AAC GTT CTT CGG GGC G, phosphorothioate-modified, from MWG
Biotech AG) mixed with 30  l of a cationic liposome preparation
(DOTAP; F. Hoffmann-La Roche Ltd.) and 170  l PBS in a polystyrene
tube. The preparation was injected using a glass syringe. MCMV infections
were initiated on day zero by intraperitoneal injection of 5   104 plaque-
forming units of salivary gland–extracted MCMV, Smith strain. For all in
vivo treatment, at the indicated time point, mice were killed by CO2 inha-
lation, and spleens were collected for further analysis. If isolated spleen cells
were needed, spleens were crushed in cold PBS supplemented with 5%
(vol/vol) heat-inactivated FCS and 0.5 mM EDTA (Sigma-Aldrich) (PBS-
FCS-EDTA) and passed through a 25-G needle. RBCs were lysed in
NH4Cl solution (StemCell Technologies, Inc.) for 5 min at 4 C. Spleen
DCs were enriched from total spleen cells by positive selection using
CD11c  Microbeads and MiniMacs (Miltenyi Biotec).
For analysis of in vivo cytokine and chemokine production, blood was
collected by cardiac puncture at the indicated time point after treatment.
Serum was prepared from whole blood by coagulation for 30 min at 37 C
and centrifugation. Sera were titrated for mouse IFN-  using specific
ELISA (PBL Biomedical Laboratories) and for mouse natural type I IFN us-
ing a conventional cytopathic effect inhibition bioassay on L-929 cells
(CCL-1; American Type Culture Collection), infected with Encephalomyo-
carditis virus (EMCV, VR-129B, ATCC). All biological assays were per-
formed in the presence of a neutralizing rat anti–mouse IFN-  mAb (clone
R4-6A2), produced in the laboratory. When needed, the assay was per-
formed in the presence of a mixture of neutralizing rabbit anti-IFN  and
IFN  pAb (PBL Biomedical Laboratories). CXCL9, CXCL10, and CCL21
were assayed using specific ELISA (R&D Systems).
Cell sorting and in vitro activation. Isolated spleen cells were incu-
bated for 30 min at 4 C with a mixture of rat anti-CD3 molecular complex
(17A2), anti-CD8  (53–5.8), anti-CD19 (1D3), or anti-erythrocyte
(TER119). Cells and goat anti–rat IgG-coated Dynabeads (Dynal) were
mixed under continuous agitation for 15 min at 4 C. Beads and attached
cells were removed using a Dynal magnet. Depleted cells were stained with
anti-pDC mAb 120G8-Alexa 488 (31), rat anti-CD8  (53 6.7)-PerCp-
Cy5.5, and hamster anti-CD11c (HL-3)-APC for 30 min at 4 C and sorted
using a FACSVantage flow cytometer (Becton Dickinson). Sorted cells
were washed, resuspended in complete medium, and cultured at 0.5   106
cells/ml in 96-well culture plates, for 24 h, in the presence of LPS at 10  g/
ml, resiquimod (R-848) at 10  g/ml, or CpG-ODN at 10  g/ml.
FACS analysis. For detection of intracellular IFN- , 10  g/ml Brefeldin
A (Sigma-Aldrich) was added during the DC enrichment procedure. Cells
were first processed with the Fix & Perm kit (BD Biosciences) according to
the manufacturer’s instructions and then sequentially stained with a mixture
of two anti–IFN-  mAbs (F18, Hycult Biotechnology, and RMMA-1,
PBL Biomedical Laboratories), goat anti–rat biotin (Jackson ImmunoRe-
search Laboratories), streptavidin-PE (DakoCytomation) and rat IgG in ex-
cess (Sigma-Aldrich). Cells were finally stained for extracellular markers us-
ing 120G8-Alexa 488 and hamster anti-CD11c (HL-3)-APC antibodies.
For analysis of freshly isolated DC activation, total spleen cells were stained
with 120G8-Alexa 488, rat anti-CD40 or CD86-PE, rat anti-CD8 -
PerCp-Cy5.5, and hamster anti-CD11c (HL-3)-APC for 30 min at 4 C.
For analysis of sorted DC activation, stimulated cells were stained with rat
anti-CD40 or CD86-PE. Stained cells were analyzed with a FACScan flow
cytometer (Becton Dickinson). Negative controls were performed with
corresponding rat or hamster Ig.
Immunohistological staining. After in vivo treatment, mouse spleens
were embedded in tissue freezing medium (Jung), flash frozen in liquid ni-
trogen, and stored at  80 C until further analysis. 5- m-thick cryosections
were fixed in 95% acetone (Sigma-Aldrich) at  20 C for 20 min, dried at
room temperature, and stored frozen at  20 C until staining was per-
formed. Serial sections were then rehydrated in PBS. Avidin/biotin tissue
content was neutralized using specific kit (Vector Laboratories), and peroxi-
dase tissue content was neutralized using PBS-0.3% H2O2 (Sigma-Aldrich).
Sections were first incubated with 2% normal mouse serum (DakoCytoma-
tion) to eliminate any unspecific antibody binding.
For immunohistochemistry staining, sections were stained sequentially
with unlabeled 120G8 rat mAb, anti-CD11c hamster mAb (N418; En-
dogen), anti-CXCL9, anti-CXCL10, or anti-CCL21 goat pAb (R&D Sys-
tems) for 60 min, goat anti–rat, goat anti–hamster, or rabbit anti–goat cou-
pled to biotin (Jackson ImmunoResearch Laboratories) for 60 min, and
finally extravidin-peroxidase (Sigma-Aldrich) for 30 min, revealed with
AEC (Sigma-Aldrich). Slides were mounted under coverslips with Glycer-
gel (DakoCytomation). For immunofluorescent double staining of DC and
T cell populations, sections were stained sequentially with unlabeled rat
anti-CD19 for B cells, rat ER-TR9 mAb for marginal zone macrophages
(BMA Biomedicals AG), hamster anti-CD3  for T cells, hamster anti-
CD11c (N418) for DC for 60 min, goat anti–rat or anti–hamster coupled to
Alexa 594 (Molecular Probes, Inc.) for 60 min, 2% rat serum for 30 min,
120G8 antibody coupled to biotin for 60 min, and finally streptavidin-Alexa
488 (Molecular Probes, Inc.) for 30 min. For immunofluorescent staining of
IFN-  producing cells, sections were stained sequentially with unlabeled rat
mAb anti-IFN-  (F18, Hycult Biotechnology bv) in PBS-0.1% saponin for
60 min, goat anti–rat coupled to Alexa 594 for 60 min, 2% rat serum for 30
min, rat 120G8 mAb coupled to biotin for 60 min, and finally streptavidin-
Alexa 488 for 60 min. Slides were air dried and mounted under coverslips
with one drop of Fluoromount G (Electron Microscopy Sciences).
All slides were viewed on an Axioskop epifluorescence microscope
(Carl Zeiss MicroImaging, Inc.). Pictures were taken using a MagnaFire
Digital Camera (Optronic Laboratories, Inc.). For immunofluorescent dou-
ble staining, identical sections were photographed for both fluorescent dyes,
and pictures were overlaid with ImagePro Express software (Adept Elec-
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Chemotaxis assay. Migration assays were performed using Costar Trans-
well (6.5-mm diameter, Corning, Inc.) with 2–3   105 cells/well. Enriched
DC populations were placed for 2 h in inserts with 5- m pores in the pres-
ence or absence of chemokines at 1  g/ml, and migrating cells were stained
with 120G8-Alexa 488 and hamster anti-CD11c (HL-3)-APC. The number
of migrating cells was then evaluated with a FACScan flow cytometer (Bec-
ton Dickinson). Results are expressed as migration index (ratio number of
migrating cells in chemokine/number of migrating cells in medium).
Statistical analysis. Statistical analysis of results was performed using non-
parametric Mann-Whitney test. Results are presented as means   SEM.
Online supplemental material. For analysis of pDC frequency, isolated
spleen cells from in vivo–treated mice were first counted by Trypan blue
exclusion and stained for 20 min at 4 C with 120G8-Alexa 488, hamster
anti-CD11c-APC, and a mixture of anti-CD3 –, anti-DX5–, and anti-
CD19–PE. Stained cells were analyzed with a FACScan flow cytometer
(Becton Dickinson). Negative controls were performed with corresponding
rat or hamster Ig. Online supplemental material is available at http://
www.jem.org/cgi/content/full/jem.20041930/DC1.
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